Research programme: Apolipoprtotein A-1 multimer therapeutics - ABIONYX Pharma
Alternative Names: CargomerLatest Information Update: 28 Jul 2025
At a glance
- Originator Cerenis Therapeutics
- Developer ABIONYX Pharma
- Class Apolipoprotein therapeutics; Multiprotein complexes
- Mechanism of Action Apolipoprotein A-I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer